Deal-Making

MilliporeSigma partners Innocore for sustained release tech

MilliporeSigma will offer customers access to a sustained release formulation platform for large molecule APIs through a partnership with Innocore. The bioprocessing equipment and tools subsidiary of Germany’s Merck KGaA, MilliporeSigma, has inked an agreement to be the partner for the introduction of Innocure’s SynBiosys biodegradable platform to the global biopharma market. The platform can be used to develop sustained release solutions for biologicals in injectable formulations, something MilliporeSigma said is becoming increasingly important and competitively tempting for biopharmaceutical developers.…

Repligen riding high on Protein A strategic partnerships

Repligen says strategic partnerships are strengthening its proteins business, following a quarter which saw deals inked with Navigo Proteins and Purolite. For the second quarter 2018, bioprocessing tools and equipment supplier Repligen Corporation reported total revenues of US$48 million (€42 million), up 47% on the same period last year. The firm also reported sequential gains in its proteins franchise, where revenue increased nearly 10% over the first quarter. The segment includes its Protein A chromatography ligand and cell culture capture…

Regeneron teams up and takes $100m stake in bluebird bio

Regeneron has increased its interest in cellular therapies through a T cell co-development partnership with bluebird bio. The deal sees Regeneron Pharmaceuticals and bluebird bio combine their respective tech platforms to discover, develop and commercialize an initial six candidates against tumor-specific proteins and peptides, including chimeric antigen receptor (CAR) T and other T cell receptors (TCRs). As part of the collaboration, Regeneron has invested $100 million (€87 million) in its new partner bluebird, buying 420,000 shares at a price of…

Esco Aster to transfer CAR-T tech to Chinese biomanufacturing plant

The Singapore-based CDMO will fit out Wuhan Bio-Raid Biotechnology’s facility in China with its lentiviral vector platform and bioproduction technologies. Esco Aster has signed a memorandum of understanding (MoU) to use its lentiviral vector platform and bioproduction technologies to support Wuhan Bio-Raid’s chimeric antigen receptor (CAR) T-cell therapy pipeline in China. “Under the MoU, both parties have achieved a broad understanding to increase the speed of CAR-T development in China,” Esco Aster spokesperson Ai San Yip told BioProcess Insider. This…

BioTime spinning out regenerative med firm AgeX

BioTime has received US$43 million (€37 million) from Juvenescence for a stake in AgeX and plans to spin the cell therapy subsidiary out in September. In April 2017, Californian late-stage biotech BioTime formed the subsidiary AgeX therapeutics to focus on its human aging candidates derived from regenerative stem cells. Earlier this year, fellow aging-focused firm Juvenescence made a $5 million investment in the subsidiary, and this week has upped its stake by 14.4 million shares paying BioTime $21.6 million in…

Sangamo Bets on CAR-Treg Through $84m TxCell Acquisition

CAR-Treg is the next biology of interest for gene-modified cellular therapies says TxCell, which is set to be acquired by Sangamo Therapeutics. Sangamo Therapeutics has agreed to buy French biotech TxCell for approximately €72 million (US$84 million), bolstering its pipeline with cellular immunotherapies based on regulatory T lymphocytes, or Tregs. The acquisition will help bring candidates, including TX200 for transplant rejection, through the clinic and towards commercialization, TxCell’s CEO Stephane Boissel told Bioprocess Insider. “We did not want to start…

Danaher Praises Pall for Returning Biopharma to ‘High Growth Norm’

Strong demand for single-use technologies has returned double-digit growth for Pall, contributing to a “return to normality” for Danaher Corporation’s life sciences business. For its second quarter 2018, Danaher Corporation reported total revenues across its life sciences businesses of US$1.6 billion (€1.4 billion), up 16% over the same period last year. The multinational attributed much of the growth to Pall Corporation – the filtration, separations and purification firm it acquired for $13.6 billion in 2015 – though CEO Tom Joyce…

Pluristem and Thermo Fisher Look to Plug Gaps in Cell Therapy Manufacture

Pluristem and Thermo Fisher will work to address the lack of technologies available to cell therapy manufacturers for the cultivation and processing of allogeneic products. “There is a lack of technologies for the cultivation and processing of allogeneic products whose potential is high scale production,” Yaky Yanay, president and co-CEO of Pluristem Therapeutics told BioProcess Insider. “Some of the gaps are in the technology itself, some are in the quality or the availability of raw materials.” To minimize some of…

Sonnet Selects Oncobiologics to Take I-O Assets into the Clinic

Sonnet BioTherapeutics has completed the discovery phase for its cytokine-based immunotherapy platform and begun a tech transfer to CDMO Oncobiologics. New Jersey-based biopharma firm Sonnet has announced it is planning to move its preclinical candidates towards the clinic, and has begun CMC development for up to four immuno-oncology candidates with a contract development and manufacturing organization (CDMO). John Cini, co-founder and chief scientific office of Sonnet, told BioProcess Insider the CDMO is fellow New Jersey-based firm Oncobiologics, which will manufacture…

Difficult Q4 for Avid as it Pushes to Diversify Customers and Fill Capacity

Avid Bioservices says it has worked aggressively to expand since becoming a pure-play CDMO but needs increased customer diversification and capacity utilization to secure future growth. After selling off its internal monoclonal antibody programs to Oncologie and dropping its Peregrine Pharmaceuticals tag, Avid Bioservices completed its transition to a pure contract development and manufacturing organization (CDMO). Six months on, the firm has reported a 62% year-on-year drop in its fourth quarter revenues to US$6.9 million (€5.9 million) and a fall…